Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer

Next Previous
Search
Trial Profile

A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mipicoledine (Primary)
  • Indications Adenocarcinoma; Carcinoma; CNS cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Dekk-Tec

    • Most Recent Events

    • 13 Apr 2022 Updated Results of the long term responses, tolerance and quality of survival in subjects with NSCLC involving the CNS, presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 05 Apr 2017 Results (n=53) from this and one more study (NCT02038218) presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 05 Apr 2017 Results of this and other trial (NCT02038218) presented at the 108th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top